Ardelyx, Inc. Reports Employment Inducement Grants
15 Maio 2023 - 5:05PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced that on May 8, 2023, the compensation committee of
the company’s board of directors granted two new non-executive
employees options to purchase an aggregate of 46,178 shares of the
company’s common stock, and granted five new non-executive
employees an aggregate of 52,600 Restricted Stock Units (RSUs).
Each stock option has an exercise price per share equal to $4.19
per share, which was the closing trading price of the company’s
common stock on the date of grant. The stock options and RSUs were
granted as inducements material to each employee’s decision to
enter into employment with Ardelyx, in accordance with Nasdaq
Listing Rule 5635(c)(4).
Each stock option vests over four years, with 25%
of the shares vesting on the first anniversary of the employee’s
first date of employment, and the remaining 75% of shares vesting
monthly thereafter. Each RSU vests over four years, with 25%
vesting on the first company designated quarterly RSU vest date
following the first anniversary of the employee’s first day of
employment, and the remaining 75% of shares vesting quarterly
thereafter. Each stock option has a 10-year term, and each option
and RSU is subject to the terms and conditions of the company’s
2016 Employment Commencement Incentive Plan and the award agreement
covering the grant.
About Ardelyx, Inc.Ardelyx was
founded with a mission to discover, develop and commercialize
innovative, first-in-class medicines that meet significant unmet
medical needs. Ardelyx’s first approved product, IBSRELA®
(tenapanor) is available in the United States and Canada. Ardelyx
is developing XPHOZAH® (tenapanor), a novel product candidate to
control serum phosphorus in adult patients with chronic kidney
disease on dialysis, which has completed three successful Phase 3
trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013,
for the potential treatment of elevated serum potassium, or
hyperkalemia, a problem among certain patients with kidney and/or
heart disease and an early-stage program in metabolic acidosis, a
serious electrolyte disorder in patients with CKD. Ardelyx has
established agreements with Kyowa Kirin in Japan, Fosun Pharma in
China and Knight Therapeutics in Canada for the development and
commercialization of tenapanor in their respective territories. For
more information, please visit https://ardelyx.com/ and connect
with us on Twitter, LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowieclowie@ardelyx.com
Kimia Keshtbod kkeshtbod@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024